Covid-19 roundup: Hy­drox­y­chloro­quine fails again; No­vavax lines up Warp Speed man­u­fac­tur­ing part­ner

Hy­drox­y­chloro­quine has failed in an­oth­er ma­jor tri­al.

In a new study in the New Eng­land Jour­nal of Med­i­cine, 667 ear­ly-stage hos­pi­tal­ized pa­tients were ran­dom­ized to re­ceive ei­ther stan­dard of care, the an­ti-malar­ia drug, or the an­ti-malar­ia drug plus azithromycin. Af­ter 15 days, the pa­tients in the dif­fer­ent tri­al arms showed no dif­fer­ence in clin­i­cal im­prove­ment. Those in the hy­drox­y­chloro­quine arm did, how­ev­er, have more ad­verse events: name­ly a pro­longed QT in­ter­val and an el­e­vat­ed num­ber of liv­er en­zymes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.